Research & Development
T2 Biosystems awarded 100K for Lyme panel from HHS, Steven & Alexandra Cohen Foundation
T2 Biosystems has been selected as a Phase 1 winner in a competition designed to advance the discovery of Lyme disease diagnostics.
November 7, 2022
Adaptive Biotechnologies debuts T-cell Lyme disease test
T-Detect Lyme, a blood test that aims to diagnose Lyme disease sooner, uses Adaptive's sequencing capabilities and Microsoft's cloud-scale AI (artificial intelligence) to characterize the T-cell repertoire and identify a clinical signal for disease.
June 14, 2022
Qiagen, DiaSorin debut Lyme disease assay
The test has a sensitivity of 74% and a specificity of 100% within 21 days from the first evidence of infection. It is available in markets accepting the CE Mark, and those that use the Liaison analyzer systems.
April 20, 2021
Don't let COVID-19 blunt awareness of Lyme disease
Below are the most common tick species found in the U.S.:
July 19, 2020
IGeneX reports data for tick-borne fever test
Tick-borne relapsing fever and Lyme disease (LD) are caused by two related Borrelia bacteria groups, each of which includes more than 20 species.
October 29, 2019
NIH-funded Lyme test promises better results, at the point of care
Results for an improved version of the mChip-Ld Lyme disease test, which is being developed with support from the NIH's National Institute of Allergy and Infectious Diseases (NIAID), were reported in the Journal of Clinical Microbiology online October 9.
October 16, 2019
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
FDA clears new indications for Lyme tests from Zeus
The FDA noted that Lyme disease traditionally has been diagnosed using a two-tier process to detect the presence of antibodies in a patient's blood against Borrelia burgdorferi, the tick-borne bacteria that causes Lyme disease. In this approach, clinical diagnosis was confirmed using two different types of tests, enzyme immunoassay (EIA) and western blot.
July 29, 2019
Bay Area biotech gets NIH grant for Lyme disease test
The South San Francisco-based company says that its antibody detection by agglutination-PCR (ADAP) technology platform will power a test that is far more sensitive than standard testing today, enabling earlier detection of Lyme disease, as well as helping to distinguish it from other tick-borne illnesses. Enable is working with Tulane University and Columbia University on the Lyme disease test and with other partners to develop ADAP tests for HIV and type 1 diabetes.
July 11, 2019
IGeneX survey flags gaps in tick-borne disease testing
The survey of 198 patients/customers tested between 2018 and 2019 highlights the challenges of getting a professional to make a diagnosis, as well as the financial impact of a delayed diagnosis, according to the company. IGeneX markets tests for Lyme disease, relapsing fever, babesiosis, and other conditions caused by ticks.
July 10, 2019
Qiagen and DiaSorin heed call for better Lyme disease test
Development of the test for Lyme disease, which is also called borreliosis and is transmitted by blacklegged ticks, will build on an ongoing collaboration to combine Qiagen's QuantiFeron interferon gamma release technology and DiaSorin's Lyme disease testing arrays.
June 5, 2019
Blood test data show Lyme disease rising in some states
Lyme disease is most often caused by the bacterium Borrelia burgdorferi, which is transmitted by tick bites to humans. Delays in diagnosis may result in the spread of infection to the joints, heart, and nervous system.
April 21, 2019
Page 1 of 1